10-Q: Scientific Industries Reports Q3 2026 Results Amidst Operating Losses

Scientific Industries, Inc. filed its Q3 2026 10-Q, revealing a net loss for the nine-month period, though Q3 itself showed a net income, driven by a significant gain from a prior asset disposition.

Summary

• For the nine months ended September 30, 2026, Scientific Industries reported a net loss of $2,353,100, a significant change from a net income of $692,200 in the same period of 2025.
• Total revenues for the nine months increased by 18.2% to $4,052,300, driven by both Benchtop Laboratory Equipment and Bioprocessing Systems operations.
• Gross profit percentage improved to 45.3% for the nine months of 2026 from 39.8% in 2025, attributed to higher margins in the Bioprocessing Systems Operations.
• Operating expenses decreased by 11.8% for the nine months of 2026, largely due to reductions in general and administrative and selling expenses.
• The company recorded a gain of $1,695,000 from the disposition of the Genie Division assets in September 2026.
• Cash used in operating activities was $2,475,000 for the nine months of 2026, an improvement from $4,390,700 in 2025.
• The company projects sufficient funds to support operations for at least one year, based on its current operating plan and cash from the Genie Division sale.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the continued operating losses and cash burn, despite some revenue and gross profit improvements in specific segments.

Positives

• Revenue increased by 18.2% to $4,052,300 for the nine months ended September 30, 2026, compared to the prior year period.
• Gross profit percentage improved to 45.3% for the nine months of 2026 from 39.8% in 2025, driven by higher margins in Bioprocessing Systems Operations.
• Operating expenses decreased by 11.8% for the nine months of 2026, indicating successful cost-saving initiatives.
• The company reported a net income of $470,000 for the three months ended September 30, 2026, showing a positive trend in the most recent quarter.
• Cash used in operating activities decreased by $1,915,700 for the nine months of 2026 compared to the prior year.
• A gain of $1,695,000 was recorded from the disposition of the Genie Division assets in September 2026.
• The company projects sufficient funds to support business operations for at least one year from the issuance date of the financial statements.

Negatives

• The company reported a net loss of $2,353,100 for the nine months ended September 30, 2026, compared to a net income of $692,200 in the same period of 2025.
• The company has an accumulated deficit of $37,504,000 as of September 30, 2026.
• The company generated negative cash flows from operations of $2,475,000 for the nine months ended September 30, 2026.
• The Bioprocessing Systems Operations segment reported a loss from operations of $2,826,100 for the nine months ended September 30, 2026.
• The company's common stock is traded on the OTC market (SCND).

Risks

• The company has recorded recurring losses from operations and continued cash outflow from operating activities, raising substantial doubt about its ability to continue as a going concern for at least one year.
• The company expects to continue to generate negative cash flows from operations in the foreseeable future.
• There is no assurance that management's current operating plan to decrease expenses and increase revenues will be successful.
• One customer accounted for approximately 27% of total revenue in the three months ended September 30, 2026, indicating customer concentration risk.
• One vendor accounted for approximately 27% of total purchases in the three months ended September 30, 2026, indicating vendor concentration risk.

Future Outlook

The company projects having sufficient funds to support business operations for at least one year from the date of issuance of the financial statements, based on management's current operating plan to decrease expenses and increase revenues with new product offerings, in addition to cash generated from the Genie Division sale and related agreements.

Management Comments

• Management believes that all adjustments necessary for a fair presentation of the interim statements have been included and are of a normal and recurring nature.
• Management expects to continue to generate negative cash flows from operations in the foreseeable future.
• Management is implementing a plan to decrease expenses and increase revenues with new product offerings.
• Management has evaluated the effectiveness of the company's disclosure controls and procedures and concluded they were effective as of September 30, 2026.

Industry Context

StockSavvy.ai notes that the laboratory equipment and bioprocessing systems sectors are subject to innovation cycles and regulatory scrutiny. The company's focus on higher-margin products within Bioprocessing Systems, such as the DOTS product line, aligns with industry trends towards specialized and advanced analytical tools.

Comparison to Industry Standards

• The company's gross profit margin of 45.3% for the nine-month period is an improvement, but specific industry benchmarks for comparable niche bioprocessing and laboratory equipment manufacturers would be needed for a precise comparison.
• The significant operating losses and accumulated deficit are concerning and may indicate challenges in scaling operations efficiently compared to larger, more established players in the life sciences and laboratory equipment sectors.
• The reliance on equity financings historically and the current projection of sufficient funds for only one year suggest a potentially less stable financial footing than industry leaders who may have more diversified funding sources or stronger organic cash generation.

Legal Proceedings

• As of September 30, 2026, and December 31, 2025, the company is not aware of any contingent legal liabilities that should be reflected in the unaudited condensed consolidated financial statements.

Related Party Transactions

• The company has a consulting agreement with John Nicols, a Director, for services to the Bioprocessing Systems Operations segment. His monthly consulting fee was reduced by 50% to $4,000 per month for the twelve-month period beginning February 1, 2026.
• During the three months ended September 30, 2026, $12,000 was paid to Mr. Nicols.
• During the nine months ended September 30, 2026, $40,000 was paid to Mr. Nicols.

Stakeholder Impact

• Shareholders may be concerned by the continued operating losses and accumulated deficit, despite improvements in revenue and gross margins.
• Employees may be impacted by past workforce reductions and the ongoing focus on cost savings.
• Creditors and suppliers may be monitoring the company's liquidity and ability to meet its financial obligations, although the company projects sufficient funds for the next year.

Next Steps

• Continue to execute the operating plan to decrease expenses and increase revenues with new product offerings.
• Monitor cash flow and ensure sufficient funds to support business operations for at least one year.
• Further develop and market new products for the Bioprocessing Systems Operations.
• Continue to manage and reduce operating expenses across all segments.

Key Dates

Recommendation

The company shows signs of operational improvement with increased revenue and better gross margins, particularly in its Bioprocessing Systems segment. However, the persistent net losses, significant accumulated deficit, and negative operating cash flow, coupled with the projection of only one year of operational runway, present substantial risks. The gain from the asset sale is a one-time event. Therefore, a 'hold' recommendation is appropriate, pending sustained profitability and a clearer path to long-term financial stability.

Keywords

Laboratory Equipment, Bioprocessing Systems, Financial Statements, Revenue, Operating Loss, Cash Flow, Asset Disposition, Form 10-Q